ms1819-sd
Recombinant proteinexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 27, 2017 (NCT03481803)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Elastase 1Supplementation
CELA1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ms1819-sd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05719311 | Phase 2 | Feb 1, 2023 | First Wave Bio, Inc. |
| NCT04375878 | Phase 2 | Jul 1, 2020 | AzurRx |
| NCT04302662 | Phase 2 | Jun 27, 2019 | AzurRx |
| NCT03746483 | Phase 2 | Jan 10, 2019 | AzurRx |
| NCT03481803 | Phase 2 | Jan 27, 2017 | AzurRx |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AzurRx | For profit | 4 | 4 | 1 | 2017 |
| First Wave Bio, Inc. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1